Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Reactions02:06

Allergic Reactions

33.1K
Overview
33.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.1K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.1K
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

94
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
94

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of HERV-K (HML-2) in amyotrophic lateral sclerosis patients on antiretroviral therapy.

Journal of the neurological sciences·2021
Same author

[Applications of artificial intelligence to new drug development].

Annales pharmaceutiques francaises·2021
Same author

Characterization of epitope specificities of reference antibodies used for the quantification of the birch pollen allergen Bet v 1.

Allergy·2017
Same author

Validation of ELISA methods for quantification of the major birch allergen Bet v 1 (BSP090).

Pharmeuropa bio & scientific notes·2017
Same author

Physical performance in newly diagnosed hypothyroidism: a pilot study.

Journal of endocrinological investigation·2017
Same author

Novel approaches and perspectives in allergen immunotherapy.

Allergy·2017
Same journal

Impact of cognitive impairment and depression on asthma in older patients.

The journal of allergy and clinical immunology. In practice·2026
Same journal

Refractory Atopic Dermatitis Unmasking Mycosis Fungoides During Targeted Therapy.

The journal of allergy and clinical immunology. In practice·2026
Same journal

ASTHMA CONTROL BEFORE AND AFTER CHANGING GAS STOVES TO ELECTRIC STOVES.

The journal of allergy and clinical immunology. In practice·2026
Same journal

Multiplex Cytokine LTT Reveals Strong T Cell Responses to Multiple Drugs in NIDHR-Associated Multiple Drug Hypersensitivity.

The journal of allergy and clinical immunology. In practice·2026
Same journal

Allergic Fungal Rhinosinusitis: Distinct Clinical Features, Diagnostic Challenges, and Evolving Therapeutic Strategies.

The journal of allergy and clinical immunology. In practice·2026
Same journal

Effectiveness of treatment with tezepelumab in patients with severe asthma, smoking asthmatics and patients with severe Asthma and COPD: A real-world cohort study.

The journal of allergy and clinical immunology. In practice·2026
See all related articles

Related Experiment Video

Updated: Mar 9, 2026

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.7K

Enhancing Allergen-Presentation Platforms for Sublingual Immunotherapy.

P Moingeon1, V Lombardi1, V Baron-Bodo1

  • 1Research and Development, Stallergenes Greer, Antony, France.

The Journal of Allergy and Clinical Immunology. in Practice
|January 10, 2017
PubMed
Summary
This summary is machine-generated.

Sublingual immunotherapy (SLIT) can be improved by using allergen-presentation platforms. These platforms enhance allergen uptake by immune cells, potentially increasing SLIT efficacy and reducing allergen doses for type I allergies.

Keywords:
AdjuvantAllergy vaccinesDelivery systemImmunopotentiatorSublingual immunotherapyVector system

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.9K
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.0K

Related Experiment Videos

Last Updated: Mar 9, 2026

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.7K
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.9K
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.0K

Area of Science:

  • Immunology
  • Allergy Treatment
  • Drug Delivery Systems

Background:

  • Sublingual immunotherapy (SLIT) uses high allergen doses for type I allergies.
  • Current SLIT lacks adjuvants or delivery systems, limiting efficacy.
  • Targeting oral dendritic cells can elicit regulatory immune responses.

Purpose of the Study:

  • To review adjuvants and vector systems for allergen-presentation platforms in SLIT.
  • To explore strategies for enhancing allergen availability and immune system targeting.
  • To identify methods for improving SLIT efficacy and reducing allergen dosage.

Main Methods:

  • Overview of potential allergen-presentation platforms for sublingual administration.
  • Discussion of adjuvants stimulating TH1 and regulatory CD4+ T-cell responses.
  • Exploration of mucoadhesive particulate vector systems for allergen delivery.

Main Results:

  • Candidate platforms include vitamin D3, glucocorticoids, TLR ligands, and probiotics.
  • Mucoadhesive particulate systems can enhance allergen uptake by tolerogenic dendritic cells.
  • Improved allergen availability is key to enhancing SLIT efficacy.

Conclusions:

  • Allergen-presentation platforms offer a promising strategy to improve SLIT.
  • Targeted delivery systems can enhance allergen capture and immune modulation.
  • Optimizing SLIT with novel platforms may reduce treatment burden and improve outcomes.